Background: Endothelin-1 (ET-1) may play an important role in the development and maintenance of hypertensive states. In patients with essential hypertension, ET-1 plasma concentration increases or remains unchanged. The aim of the present study was to investigate ET-1 plasma concentration in patients with mild-to-moderate essential hypertension and its interrelationship with catecholamines, neuropeptide Y and atrial natriuretic peptide (ANP).
Methods: The study included 37 patients (mean age 38.2 ± 1.6 years) with mild-to-moderate essential hypertension. The control group consisted of 21 healthy volunteers (mean age 35.6 ± 1.4 years). ET-1, neuropeptide Y and ANP were determined by radioimmunoassay methods and catecholamine plasma concentration was determined radioenzymatically.
Results: Our study shows that plasma ET-1 and neuropeptide Y levels are elevated in patients with essential hypertension compared with a control group. No correlation was found in either of the groups between plasma ET-1 level and plasma neuropeptide Y, catecholamine or ANP concentrations.
Conclusion: Our results suggest that ET-1 is relevant in the development and maintenance of elevated blood pressure.
LuscherT: The endothelium: Target and promoter of hypertension? Hypertension1990, 15:482–485.
2.
LermanAHildebrandFMarguliesKO'MurchuBPerrellaMHeubleinD: Endothelin: A new cardiovascular regulatory peptide. Mayo Clin Proc1990, 65:1441–1455.
3.
VanhoutteP: Is endothelin involved in pathogenesis of hypertension? Hypertension1993, 21:747–751.
4.
LuscherTBockAYangZDiederichD: Endothelium-derived relaxing and contracting factors: Perspectives in nephrology. Kidney Int1991, 39:575–590.
5.
WinquistRScottAValsukG: Enhanced release of atrial natriuretic factor by endothelin in atria from hypertensive rats. Hypertension1989, 14:111–114.
6.
StaschJHirth-DietrichCKazdaSNeuserD: Endothelin stimulates release of atrial natriuretic peptide in vitro and in vivo. Life Sci1989, 45:869–875.
7.
KohnoMYasunariKYokokawaKMurakawaKHorioTTakedaT: Inhibition by atrial and brain natriuretic peptide of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J Clin Invest1991, 87:1999–2004.
8.
ValentinJPGardnerDWiedemannEHumphreysM: Modulation of endothelin effects on blood pressure and hematocrit by atrial natriuretic peptide. Hypertension1991, 17:864–869.
9.
WilkesLBoarderM: Characterization of the endothelin binding site on bovine adrenomedullary chromaffin cells: Comparison with vascular smooth muscle cells. Evidence for receptor heterogeneity. J Pharmacol Exp Ther1991, 256:628–633.
10.
SoneMTotsuneKTakahashiKOhnedaMItoiKMurakamiO: Immunoreactive endothelin in pheochromocytomas. J Cardiovasc Pharmacol1991, 17:427–429.
11.
YangZRichardVvon SegesserLBauerEStulzPTurinaM: Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation1990, 82:188–195.
12.
SaitoYNakaoKMukoyamaMShirikamiGItohHYamadaT: Application of monoclonal antibodies for endothelin in hypertensive research. Hypertension1990, 15:734–738.
13.
SchiffrinEThilbaultG: Plasma endothelin in human essential hypertension. Am J Hypertens1991, 4:303–308.
14.
ShichiriMHirataYAndoKEmoriTOhtaKKimotoS: Plasma endothelin levels in hypertension and chronic renal failure. Hypertension1990, 15:493–496.
15.
DavenportAAshbyMEastonPEllaSBedfordJDickersonC: A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci1990, 78:261–264.
16.
KohnoMMurakawaKHorioTYokokawaKYasunariKFukuiT: Plasma immunoreactive endothelin-1 in experimental malignant hypertension. Hypertension1991, 18:93–100.
17.
DalyRRobertsMRuffoloRJrHiebleJ: The role of neuropeptide Y in vascular sympathetic neurotransmission may be enhanced in hypertension. J Hypertens1988, 6 (suppl 4):S535–S538.
18.
ErlingeDEkmanRThulinTEdvinssonL: Neuropeptide Y-like immunoreactivity and hypertension. J Hypertens1992, 10:1221–1225.
